Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + seribantumab
- Development stage
- Discontinued
- Lead developer
- Concentra Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + seribantumab is a combination therapy consisting of docetaxel, a taxane chemotherapy agent, and seribantumab, a fully human IgG2 monoclonal antibody that targets HER3 (ErbB3). Seribantumab works by blocking heregulin (HRG) binding to HER3 and downregulating the receptor, which inhibits downstream signaling pathways involved in tumor growth. This combination was investigated for the treatment of heregulin-positive non-small cell lung cancer (NSCLC).
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + seribantumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + seribantumab.